Price Chart

Profile

Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic approach to select patients based on their tumors' underlying genetics rather than histology. The company's product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, the company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
URL https://www.rainoncology.com
Investor Relations URL https://investors.rainoncology.com/
HQ State/Province California
Sector  
Industry  
Equity Style Small Cap/Value
Next Earnings Release Mar. 08, 2024 (est.)
Last Earnings Release Nov. 09, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic approach to select patients based on their tumors' underlying genetics rather than histology. The company's product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, the company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
URL https://www.rainoncology.com
Investor Relations URL https://investors.rainoncology.com/
HQ State/Province California
Sector  
Industry  
Equity Style Small Cap/Value
Next Earnings Release Mar. 08, 2024 (est.)
Last Earnings Release Nov. 09, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A